Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the effects of niraparib in those who have received neoadjuvant
chemotherapy and subsequent interval debulking surgery, with or without hyperthermic
intraperitoneal chemotherapy, and would also explore if there are any biomarkers, other than
BRCA / HRD status and platinum sensitivity, that may help to identify those who may benefit
from PARPi especially those who are HRD negative.